IGC Pharma (IGC) EBIT (2010 - 2025)

IGC Pharma (IGC) has 16 years of EBIT data on file, last reported at -$2.9 million in Q3 2025.

• EBIT for Q3 2025 came in at -$2.9 million, down 64.72% year-over-year; the trailing twelve-month figure through Sep 2025 was -$8.1 million (down 258.82% YoY), and the FY2026 annual result was -$2.5 million, down 64.41% from the prior year.
• EBIT retreated to -$2.9 million in Q3 2025 per IGC's latest filing, from -$1.9 million in the prior quarter.
• Over five years, EBIT peaked at $5.8 million in Q1 2022 and troughed at -$4.3 million in Q3 2021.
• A 5-year average of -$868578.9 and a median of -$2.2 million in 2021 frame the typical range for EBIT.
• The sharpest annual moves came in 2021 and 2022: EBIT plunged 159.43% in 2021, then soared 42.78% in 2022.
• A 5-year view of EBIT shows it stood at -$2.4 million in 2021, then rose by 4.49% to -$2.3 million in 2022, then slumped by 31.61% to -$3.0 million in 2023, then surged by 37.36% to -$1.9 million in 2024, then tumbled by 54.37% to -$2.9 million in 2025.
• Business Quant data shows IGC's EBIT at -$2.9 million in Q3 2025, -$1.9 million in Q2 2025, and -$1.4 million in Q1 2025.